{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "MSIF News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "People With MS News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "Research News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

{{if listFind(vars.channel_names, "MS Society News")}}

{{endif}}

Atlas of MS poster presented at ECTRIMS

Much interest was shown in MSIF's Atlas of MS poster presented by Alan Thompson, Chairman of MSIF's International Medical and Scientific Board, and Paul Rompani, MSIF's Deputy Chief Executive, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The poster was presented in anticipation of the launch of the Atlas of MS publication in April 2007.

To read the poster, download the PDF here: AtlasofMSPoster.pdf (151 kb)

MSIF stand at ECTRIMS

The MSIF exhibit at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was visited by hundreds of people over the four days of the conference, held in Madrid, Spain, from 27-30 September 2006.

read more

Quality of Life Principles presented at Madrid06 conference

Paul Rompani, MSIF's Deputy Chief Executive, was a speaker at the Madrid06 conference, which took place on September 26 in Madrid, Spain.

read more

back to top

Profile of the Month : January 2008

Mohammad

Country: Thailand
Age: 34
Year of diagnosis: 1998
Occupation: Quality Control Manager

English Spanish Italian French Russian

read more

back to top

Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct

This study suggests that patients with and without oligoclonal bands, which are markers of inflammation commonly found in the spinal fluid of patients with MS, may have different genetic subtypes.

authors: Imrell K, Landtblom AM, Hillert J, Masterman T.

source: Neurology. 2006 Sep 26;67(6):1062-4.

read more

Baseline MRI predicts future attacks and disability in clinically isolated syndromes

This seven year study in 156 patients with a single clinical episode suggestive of inflammation showed that MRI performed at the initial presentation could be used to predict the chances of conversion to clinically definite MS.

authors: Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, Pelayo R, Comabella M, Sastre-Garriga J, Montalban X.

source: Neurology. 2006 Sep 26;67(6):968-72.

read more

Neocortical neuronal, synaptic, and glial loss in multiple sclerosis

This post mortem study describes degenerative changes found in MS with a view to better targeting of novel therapies.

authors: Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM.

source: Neurology. 2006 Sep 26;67(6):960-7.

read more

Is late-onset multiple sclerosis associated with a worse outcome?

This study on 2,837 patients showed that the age of patients at the onset of MS did not affect how quickly they became disabled.

authors: Tremlett H, Devonshire V

read more

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis

This paper on 27 patients suggests that continued use of Glatiramer Acetate may prolong the immunosuppressive effect of mitoxantrone in patients with active relapsing remitting MS, and may allow a reduction in initial mitoxantrone therapy.

authors: Ramtahal J, Jacob A, Das K, Boggild M.

source: J Neurol. 2006 Sep 21; [Epub ahead of print]

read more

Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial

This report on 13 patients who took a synthetic cannabinoid called Nabilone showed a reduction of pain on the drug, but no effect on other symptoms. The drug was considered safe and easily administered.

authors: Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD.

source: J Neurol. 2006 Sep 20; [Epub ahead of print]

read more

Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models

This study presents work in a mouse model of MS. Results suggest that Nicotinamide administration may protect axons from degeneration, even if given late, and may be a potential treatment for MS.

authors: Kaneko S, Wang J, Kaneko M, Yiu G, Hurrell JM, Chitnis T, Khoury SJ, He Z.

source: J Neurosci. 2006 Sep 20;26(38):9794-804.

read more

back to top

Fampridine improves walking speed and leg strength in MS, announces drug company

source: US National MS Society

Acorda Therapeutics announced positive results of a Phase 3, controlled clinical trial of Fampridine-SR, an oral drug designed to provide symptomatic relief by compensating for lost nerve conduction. The placebo-controlled study involved 301 patients with all types of multiple sclerosis at 33 sites in the US and Canada. The primary outcome measured was improvement in the time it took to walk 25 feet.

read more

Raising MS awareness in France

source: French MS Society

The French MS days for 2006 will take place from 7-8 October.

read more

back to top

Tell a friend

The email you subscribed with us is {{print email}}

Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.

If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.

If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here

Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org

 Click here to learn more about the work of the Making Connections sponsor.